Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Osteoarthritis Cartilage. 2014 Nov 25;23(3):443–453. doi: 10.1016/j.joca.2014.11.013

Figure 3. Chondrogenic differentiation of FGF2-expanded hMSC in the presence of FGF9 or FGF18 (and variants) at different times of initial stimulation.

Figure 3

FGF9, FGF18 or their variants were administered starting at the beginning (d0), at day 7 (d7) and at day 14 (d14) of chondrogenic differentiation until day 21. (A) Histological assessment of representative pellets showing the anabolic effect when stimulation starts at d14, and a negative effect when started earlier, specifically FGF9. Pellet shown in the insert (control) corresponds to black dots shown on B). (B) GAG/DNA quantification and aggrecan gene expression analysis assessed by qRT-PCR, performed at day 21. Statistical significance (#) was obtained for GAG/DNA comparing all values to control pellet (black dots) with the following p values: β+9 (d0: 0.0010; d7: 0.0011; d14: 0.0017); β+9v1 (d14: 0.0001); β+18 (d14: 0.0021); β+18v3 (d14: 0.0008). All other comparisons were p > 0.2. For Aggrecan, significance (#) gave the following p values: β+9 (d0: 0.0009; d7: 0.0021); β+9v1 (d14: 0.0011); β+18 (d0: <0.0001; d7: <0.0001); β+18v3 (d14: 0.0007). All other comparisons were p > 0.2. N=4.